Understanding Prograf: A Comprehensive Guide to Tacrolimus
Prograf operates by binding to an intracellular protein known as FKBP-12. This complex then inhibits calcineurin, a crucial enzyme in T-cell activation. As a result, the production of interleukin-2 (IL-2) is suppressed, leading to reduced T-cell proliferation and a weakened immune response .(CenterWatch, Wikipedia)
Prograf is primarily prescribed for: Preventing organ rejection in liver, kidney, or heart transplant recipients.
in liver, kidney, or heart transplant recipients. Managing ongoing rejection episodes in transplant patients.
Treating certain autoimmune conditions, such as lupus nephritis and atopic dermatitis, when other treatments are ineffective.(Houston Chronicle, PharmaServe)
The dosage of Prograf is individualized based on the type of transplant, the patient's weight, and blood tacrolimus levels. Typically, it is administered twice daily, either orally or intravenously. It's crucial to take Prograf on an empty stomach, either one hour before or two hours after meals, to ensure optimal absorption .(PharmaServe, patient-info.co.uk,
Common side effects include: Tremors
Headache
Nausea and vomiting
Diarrhea
Hypertension(PharmaServe, Practo)
Serious side effects may involve kidney dysfunction, increased risk of infections, and certain cancers. Regular monitoring through blood tests is essential to detect and manage these risks .(PharmaServe)
Prograf can interact with various medications, potentially altering its effectiveness or increasing side effects. For instance, drugs that inhibit the enzyme CYP3A, such as ketoconazole, can increase tacrolimus levels, while CYP3A inducers like rifampin can decrease its levels .(PharmaServe)
Before starting Prograf, inform your healthcare provider if you have:(Drugs.com) Liver, kidney, or heart conditions unrelated to your transplant.
A history of diabetes or high blood pressure.
Any allergies to tacrolimus or other medications.(Drugs.com)
Pregnant or breastfeeding women should use Prograf only if absolutely necessary, as it can affect the unborn baby or pass into breast milk .(PharmaServe)
Regular follow-up appointments are crucial for patients on Prograf. These visits typically include:(patient-info.co.uk, Drugs.com) Blood tests to monitor tacrolimus levels and organ function.
Assessments for signs of infection or other complications.
Adjustments to the dosage based on test results and overall health status.
Prograf is a vital medication for transplant recipients, aiding in the prevention of organ rejection. While it offers significant benefits, it's essential to be aware of potential side effects and interactions. Adhering to prescribed dosages, attending regular medical check-ups, and maintaining open communication with healthcare providers can help ensure the best outcomes for patients on Prograf therapy.(Houston Chronicle)
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Crinetics Pharmaceuticals, Inc. (CRNX)' Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data
We recently compiled a list of Crinetics Pharmaceuticals, Inc. stands fifth on our list. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly. At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly. The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients. A scientist in a laboratory looking into a microscope, researching advances in biopharmaceuticals for central nervous system disorders. Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
Common Viruses May Wake Dormant Breast Cancer Cells, Study Finds
Breast cancer patients who have been in remission for years or even decades may still need to be cautious about respiratory infections. Some common viruses may re-awaken a very small number of dormant breast cancer cells within our lungs, according to emerging research. "Dormant cancer cells are like the embers left in an abandoned campfire, and respiratory viruses are like a strong wind that reignites the flames," argues molecular geneticist James DeGregori from the University of Colorado. Related: The research began following the COVID-19 pandemic, when DeGregori and his colleagues began to notice a curious uptick in cancer cases. To find out more, the international team turned to human population studies and mouse models. They found that patients in remission for cancer in the UK Biobank who tested positive for SARS-CoV-2 later showed a twofold increase in cancer-related death. "The extent of this increased risk is almost unheard of in epidemiology for cancer," says epidemiologist Roel Vermeulen from Utrecht University in The Netherlands. "It's a significant effect." That's not all researchers found, either. Analyzing a separate breast cancer database from the United States, including nearly 37,000 patients, they discovered that a previous SARS-CoV-2 infection was associated with a greater than 40 percent increased risk of metastatic breast cancer in the lungs. Studies in mice suggest that viruses might be behind the spread. Influenza and SARS-CoV-2 infections triggered dormant breast cancer cells in mice to proliferate after only days of infection. Within two weeks, there was "a massive expansion of carcinoma cells into metastatic lesions" by more than 100-fold, write the authors, led by molecular geneticist Shi Chia from the University of Colorado. "Although species differences warrant caution in interpreting mouse data… collectively, these findings underscore the substantial metastatic risk COVID-19 posed to cancer survivors," warn the team. For years now, scientists have suspected that some highly common viruses, like the Epstein-Barr Virus (EBV), have the potential to trigger certain cancers. The human papillomavirus (HPV) is already known to do this. That's why the HPV vaccine has proved so life-changing for millions. It prevents deadly, viral-associated diseases, like cervical cancer. Since 1936, scientists have been searching for a virus that triggers breast cancer in a similar way, mostly in mice and human population studies. High-risk viruses have been detected in human breast cancer samples. EBV, for instance, is five times higher in breast cancer tissue than in normal tissue. But while the idea that viruses may predispose us to cancer is plausible, research in human cells is limited, and the mechanism underlying the disease spread remains undetermined. The immune system's response to viruses could possibly play a role. After initial remission, a tiny number of breast cancer cells can remain dormant in lung, bone, and liver tissue. Sometimes, inflammation can wake these cancer cells up – and viral respiratory infections, like the flu and COVID-19, can cause inflammation. In the current mouse experiments, the influenza A virus only reawakened dormant cancer cells in the lung if they triggered an increase in inflammatory cytokines, such as IL-6. The same was true of the coronavirus. The findings suggest that the immune system's response to viruses breeds the perfect environment for cancer to proliferate. "What our data suggest is that if you are a cancer patient who has these dormant cells, you may end up living a normal life and dying with these dormant cells, instead of dying because those dormant cells awakened," says DeGregori. "But if you get a respiratory virus like influenza or COVID, your chance of dying from those dormant cells awakening is much greater." If that's true, then it will be vital to protect the millions of breast cancer survivors out there who may face an increased risk of relapse if they get sick. Further research is needed to see if vaccination against influenza or COVID-19 can help. The study was published in Nature. Related News Study Reveals The Shocking Amount of Plastic We Breathe in Every Day Researchers Identified New Blood Group After 50 Year Mystery Sleepiness Could Be Triggered by a Power Overload in Our Brain Solve the daily Crossword
Hamilton Spectator
2 days ago
- Hamilton Spectator
Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines
TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. ('Medicenna' or the 'Company') (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for oncology and autoimmune diseases, today announced grant of five patents covering the Company's IL-2 and IL-4 Superkine platforms. These patents strengthen Medicenna's intellectual property (IP) position across key markets and further support the Company's lead clinical and preclinical programs. The newly granted patents cover composition, formulation, combination, use, and therapeutic applications of IL-2 and IL-4 Superkines. Newly granted patents span major markets, with anticipated expiration dates ranging from 2033 to 2040 depending on the specific case and local rules, without accounting for any potential extensions. Patents granted include: 'These newly granted and allowed patents not only expand the breadth and depth of our intellectual property portfolio but also enhance the long-term commercial potential of our Superkine programs,' said Fahar Merchant, Ph.D., President and CEO of Medicenna. 'Notably, the patent covering IL-2 superagonists in combination with anti-PD1 antibodies provides important coverage for MDNA11, which is being evaluated in the ongoing Phase 1/2 ABILITY-1 study, reinforcing both the clinical rationale and commercial potential. Furthermore, protection granted to a novel formulation of bizaxofusp (MDNA55), used in the Phase 2b recurrent glioblastoma clinical trial, solidifies its commercial exclusivity for treatment of brain cancers as we pursue potential partnering of this Phase 3 ready asset. By strengthening long-term protection for our proprietary IL-2 and IL-4 assets across key jurisdictions, we are laying the foundation for durable competitive advantage and sustained shareholder value. We look forward to sharing additional clinical data from the ABILITY-1 clinical trial during the balance of this calendar year.' Medicenna's global IP portfolio now comprises 86 granted or allowed patents, supporting a robust and diverse clinical pipeline. About Medicenna Therapeutics Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna's long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna's early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Medicenna's early-stage BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and the T-MASK™ (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically 'cold' tumors. For more information, please visit , and follow us on X and LinkedIn . Forward-Looking Statements This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook, intellectual property protection, clinical and commercial potential, competitive position and shareholder value creation or or other statements that are not historical facts. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage pre-clinical or clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented. Forward-looking statements are often identified by terms such as 'will', 'may', 'should', 'anticipate', 'expect', 'believe', 'seek', 'potentially' and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements. This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release. Investor/Media Contact: Shushu Feng Investor Relations, Medicenna Therapeutics ir@
